Ad
related to: empagliflozin brand name in india- JARDIANCE Guidelines
Learn About JARDIANCE Guidelines
For Healthcare Professionals
- JARDIANCE Safety Data
Safety & Warning Information For
US Healthcare Professionals.
- JARDIANCE Coverage
JARDIANCE Co-Pay Program
Search For Patient Coverage.
- JARDIANCE Dosing Data
Dosing Considerations And Data
For Healthcare Professionals.
- JARDIANCE Guidelines
Search results
Results From The WOW.Com Content Network
Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. [ 10 ] [ 2 ] [ 12 ] It is taken by mouth .
Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
Empagliflozin should each be stopped at least three days before scheduled surgery. Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. History. The combination preparation was developed and marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. References
Dapagliflozin is used along with diet, exercise, and usually with other glucose lowering medications, to improve glycaemic control in adults with type 2 diabetes. Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when ...
Ipragliflozin ( INN, [2] : 69 trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, [3] and in Russia on May 22, 2019. [4]
Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes. [3] [4]The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.
Empagliflozin/metformin was approved for use in the European Union in May 2015. [5] Empagliflozin/metformin was approved for use in the United States in August 2015. [6] [11] The extended release version was approved for use in the United States in December 2016. [12] [13] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]
Ad
related to: empagliflozin brand name in india